Premium
Immunohistochemical expression of DNA methyltransferases 1, 3a, and 3b in actinic cheilitis and lip squamous cell carcinomas
Author(s) -
Daniel Filipe I.,
Alves Soraia R.,
Vieira Daniella S. C.,
Biz Michelle T.,
Daniel Inah W. B. S.,
Modolo Filipe
Publication year - 2016
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12453
Subject(s) - carcinogenesis , methyltransferase , immunohistochemistry , dna methylation , cancer research , methylation , epigenetics , cancer , dna methyltransferase , pathology , biology , medicine , dna , gene expression , gene , genetics
Background Epigenetic modifications, including DNA methylation of tumor suppressor genes carried out by DNA methyltransferases ( DNMT s), are important events in carcinogenesis. Although there are studies concerning to its expression in several cancer types, DNMTs expression pattern is not known in photoinduced lip carcinogenesis. The aim of this study was to investigate the immunoexpression of DNMT s 1, 3a, and 3b in lip precancerous lesion (actinic cheilitis) and cancer. Methods Thirty cases of actinic cheilitis ( AC ), thirty cases of lip squamous cell carcinoma ( LSCC ), and twenty cases of non‐neoplastic tissue ( NNT ) were selected for immunohistochemical investigation of DNMT s 1, 3a, and 3b. Results Nuclear DNMT 1 immunoreactivity was significantly higher in the LSCC group (68.6%) compared with NNT (47%), and nuclear DNMT 3b was higher in LSCC (70.9%) than in NNT (37.9%) and in AC (44%). Only DNMT 3a showed both higher nuclear and cytoplasmic expression in AC (35.9% and 35.5%, respectively) than in NNT (4.4% and 16.1%, respectively) and LSCC (8.8% and 13.2%, respectively) ( P < 0.05). Conclusions The results suggested that DNMT 3a could play a key role in the methylation process of initial steps of UV carcinogenesis present in AC while DNMT 3b could be responsible for de novo methylation in already established lip cancer.